Therapeutic | Cadonilimab |
Target 1 | PDCD1 |
Heavy Chain 1 | QVQLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA |
Light Chain 1 | DIQMTQSPSSMSASVGDRVTFTCRASQDINTYLSWFQQKPGKSPKTLIYRANRLVSGVPSRFSGSGSGQDYTLTISSLQPEDMATYYCLQYDEFPLTFGAGTKLELK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | CTLA4 |
Heavy Chain 2 | QVVLVESGAEVKKPGASVKVSCKASGYSFTGYTMNWVRQAPGQCLEWIGLINPYNNITNYAQKFQGRVTFTVDTSISTAYMELSRLRSDDTGVYFCARLDYRSYWGQGTLVTVSA |
Light Chain 2 | QAVVTQEPSLTVSPGGTVTLTCGSSTGAVTTSNFPNWVQQKPGQAPRSLIGGTNNKASWTPARFSGSLLGGKAALTISGAQPEDEAEYYCALWYSNHWVFGCGTKLTVL |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific Mixed mAb and scFv |
Isotype | G1;na |
Highest Clinical Trial (Aug '23) | Phase-II |
Estimated Status (Aug '23) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2020 |
INN Year Recommended | None |
Companies Involved | Akeso Biopharma |
Conditions Approved | na |
Conditions Active | Non-small cell lung cancer, Solid tumours, Peripheral T/NK cell lymphoma, Hepatocellular carcinoma, Gastic adenocarcinoma, Nasopharyngeal carcinoma |
Conditions Discontinued | na |
Notes | (June '22: Corrected FWH1 and FWL2 sequences) |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]